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KL-6, a MUCl mucin preferentially expressed in regenerating type 2 pneumocytes, has been reported to 
be a sensitive serum marker for evaluating the disease activity of interstitial pneumonitis (IP). Type III 
procollagen N-terminal peptide (PIIIP) and type IV collagen 7S (7s collagen) have also been reported to 
be useful in the serological evaluation of the activity. Their levels were measured and their serodiagnostic 
values were compared simultaneously in patients with IP and alveolar pneumonia. The study population 
was 4.5 patients with IP and 12 patients with alveolar pneumonia. Serum KL-6 levels were measured by 
a specific enzyme immunoassay, and both serum PIIIP and 7s collagen concentrations by their 
correspondent radioimmunoassay kits. There were no significant difference of serum C-reactive protein 
level, which was evaluated as an indicator of inflammatory process, between IP and alveolar pneumonia 
patients. In IP, the abnormally elevated rate of KL-6 [SO% (36/45)] was significantly higher than those of 
PIIIP [40% (18/45)] and 7S collagen [40% (18/45)]. In alveolar pneumonia, the rate of KL-6 [0% (O/12)] 
was significantly lower than those of PIIIP [33% (4/12)] and 7S collagen [25% (3/12)]. There were no 
significant correlations among serum levels of the markers. These observations indicate that the 
serodiagnostic value of KL-6 for IP is superior to that of PIIIP and 7S collagen, and that KL-6 has a 
characteristic to discriminate IP from alveolar pneumonia. 
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Introduction 
For improved care of patients with interstitial pneu- 
monitis (IP), sensitive and convenient examinations 
indicating disease activity are desirable, as present 
examinations considered to be useful to evaluate the 
activity, such as open lung biopsy, Ga-67 citrate 
scintigram and bronchoalveolar lavage fluid (BALF), 
are seldom performed frequently or repeatedly 
because of their harmfulness and/or cost. 
KL-6, discovered by the present authors, has been 
reported to be a sensitive serum marker to evaluate 
disease activity of IP (l-5). KL-6 is classified in 
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MUCl mucins (6,7). The expression of KL-6 on 
regenerating type 2 pneumocytes was increased (2) 
and its level in BALF was increased at high rates in IP 
(8). Some reports have indicated that type III pro- 
collagen N-terminal peptide (PIIIP) (9-12) and type 
IV collagen 7S (7s collagen) (13,14) levels in serum 
and BALF from patients with interstitial pneumonitis 
might be useful for evaluating disease activity, but 
their clinical and pathophysiological significance is 
controversial at present. In this study, circulating 
levels of KL-6, PIIIP and 7S collagen were measured 
and compared in patients with interstitial pneumonitis 
and alveolar pneumonia. 
Methods and Materials 
STUDY POPULATIONS 
The study population was 45 patients with IP who 
consecutively visited the authors’ hospital, consisting 
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of 20 patients with idiopathic pulmonary fibrosis 
(IPF), 10 patients with IP associated with collagen 
vascular disease (IP-CVD), and 15 patients with IP 
whose aetiologies were different from the former 
two diseases (other IP). The CVD group consisted of 
four patients with rheumatoid arthritis, two patients 
with systemic lupus erythematous, two patients with 
dermatomyositis and two patients with mixed con- 
nective tissue disease. The other IP patients were four 
patients with radiation pneumonitis, four patients 
with pneumoconiosis, three patients with hypersensi- 
tivity pneumonitis, three patients with sarcoidosis 
and a patient with eosinophilic pneumonia. Twelve 
patients with alveolar pneumonia, as a control dis- 
ease, were included. They were diagnosed as having 
bacterial pneumonia from observation of subjective 
symptoms, chest X-ray film findings, neutrophilia, 
increased levels of acute phase reactants and/or 
responses to antibiotic therapies. Seven of them were 
bacteriologically positive. 
The age of patients with IP [59.7 f 14.0 (mean f 
SD) years] was not significantly different from that of 
patients with alveolar pneumonia (63.3 & 15.1 years, 
U=217, P=O.3). The male:female ratio was 29:16 
in IP patients and 5:7 in patients with alveolar 
pneumonia. 
QUANTIFICATION OF SERUM MARKER LEVELS 
Serum samples were frozen immediately and stored at 
- 80°C until use. Serum KL-6 level was measured by 
a sandwich type of enzyme immunoassay described 
previously (1,2). Serum PIIIP and 7s collagen levels 
were measured by commercially available radio- 
immunoassay kits, Reagnost PIIIP (Hoechst Japan, 
Tokyo) and Type IV collagen 7s kit (Nippon DPC, 
Tokyo), respectively. Serum level of C-reactive pro- 
tein was measured by latex laser nephelometry. In 
the authors’ laboratory, the normal range in serum 
was determined at the level of mean f 2SD from more 
than 100 healthy volunteers, 520 U ml - ’ or less for 
KL-6 (l), 0.3-0.8 U ml - ’ for PIIIP, 6 ng ml - ’ or less 
for 7s collagen, and less than 0.25 mg dl - ’ for 
C-reactive protein. 
STATISTICAL ANALYSIS 
Data are expressed as mean and SD, and/or median 
and range. The difference in serum marker levels 
between two diseases was tested by the Mann- 
Whitney U-test. Differences of positive and negative 
numbers between two markers were tested by the 
Chi-square test for goodness of fit or the Fisher’s 
exact probability test. Correlation between levels of 
two markers was calculated by the simple linear 
regression. Significance was accepted when PcO.05. 
Results 
Serum levels of KL-6, PIIIP and 7s collagen in 45 IP 
patients and 12 alveolar pneumonia patients are 
shown in Fig. 1. Serum KL-6 levels in IP patients 
were 2179% 3871 and 1020 (91-19 300) [median 
(range)] U ml - ‘, and were significantly higher than 
those of patients with alveolar pneumonia, which 
were 296+ 122 and 293 (142-496) Uml-’ (U=58, 
P<O.OOOl). However, there were no significant differ- 
ences in serum PIIIP or 7s collagen levels between 
patients with IP and alveolar pneumonia (U=256, 
P=O.78 for PIIIP; U=244, P=O.60 for 7s collagen). 
There was no significant difference of serum 
C-reactive protein level between IP [4.1 f 7.3 and 0.48 
(0.25-27.1) mg dl - ‘1 and alveolar pneumonia 
patients [4.9 + 6.6 and 3.66 (0.27-24.0) mg dl- r, 
U= 188, P= 0.081. In comparison between four disease 
groups, as shown in Table 1, KL-6 was significantly 
higher in IPF, IP-CVD and other IP than in alveolar 
pneumonia, but there were no significant differences 
in KL-6 levels among IPF, IP-CVD and other IP. In 
contrast, both PIIIP and 7s collagen levels were 
significantly higher in IP-CVD than in IPF. 
There were, furthermore, no significant corre- 
lations among KL-6, PIIIP and 7s collagen levels 
(PIIIP vs KL-6: r=0.04, P=O.75; 7s collagen v,s KL-6: 
r=0.06, P=O.66; 7s collagen vs PIIIP: ~~0.18, 
P=O.19). Rates of patients who revealed abnormally 
elevated levels of serum markers are shown in Table 
2. Significant differences in positive and negative 
numbers between patients with IP and alveolar 
pneumonia were observed only in KL-6. 
Discussion 
This preliminary study clarified that among the three 
serum markers, KL-6, PIIIP and 7s collagen, the 
sensitivity of KL-6 was much higher than that of 
PIIIP and 7s collagen in patients with IP. In alveolar 
pneumonia, furthermore, the sensitivity of KL-6 was 
much lower than that of the other markers. There was 
no significant difference of inflammation activity 
evaluated by serum C-reactive protein levels between 
the diseases. These observations indicate that KL-6 is 
superior to the others as a serum marker of IP, and 
that KL-6 is a marker capable of discriminating IP 
from alveolar pneumonia. Both PIIIP and 7s colla- 
gen levels, however, are increased in sera from 
patients with alveolar pneumonia, as well as in sera 
from patients with IP. 
Previous studies have disclosed the clinical and 
pathophysiological significance of the elevation of 
serum KL-6 in IP patients. The elevation of serum 
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FIG. 1. Serum levels of KL-6, type III procollagen N-terminal peptide (PIIIP) and type IV collagen 7s 
(7s collagen) in patients with interstitial pneumonitis and alveolar pneumonia. Horizontal bars indicate 
median. Dotted lines indicate cut-off values. N.S., no significance; IP, interstitial pneumonitis; Alv.P., alveolar 
pneumonia. 
TABLE 1. Serum levels of KL- 6, type III procollagen N-terminal peptide (PIIIP) and type 
IV collagen 7s (7s collagen) 
Disease n 
KL-6 
(an-‘) 
PIIIP 
(U ml-‘) 
7s collagen 
(ng ml - ‘) 
IPF 20 1268 (164-19 300)*,7 0.62 (0.3-1.6) 5.4 (2.8-7.6) 
IP-CVD 10 980 (645-1755)t 1.2 (0.43-1.9)§ 6.6 (4.8-12&s 
Other IP 15 740 (91-16 440)$ 0.68 (0.33-1.5) 5.3 (0+7+3) 
Alveolar pneumonia 12 293 (142496) 0.66 (0.5 14) 4.7 (3.7-8.2) 
*Median (range). 
t,$Significantly higher than alveolar pneumonia (tWO.0001, $P<O.O5). 
SSignificantly higher than IPF (BO.05). IPF, idiopathic pulmonary fibrosis; IP-CVD, 
interstitial pneumonitis associated with collagen vascular disease. 
KL-6 in IP patients strongly indicates the presence of 
alveolitis where regenerating type 2 pneumocytes 
produce a higher amount of KL-6 (2,s). The elevation 
of serum PIIIP levels reflects the increased production 
of type III collagen. In IPF, since the deposition of 
type III collagen is observed in the early stage of the 
fibrosis (15), it is suggested that the increase of serum 
PIIIP might indicate recent fibrogenesis. Type IV 
collagen is a component of basement membrane. The 
increase of serum 7s collagen is thought to reflect 
basement membrane disruption by inflammation 
(15). This study suggests that the increased levels of 
PIIIP and 75 collagen observed in IP-CVD might 
have originated in part from extrapulmonary lesions, 
because their levels were significantly higher in 
IP-CVD than in IPF. 
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TABLE 2. Positive rates of KL-6, type III procollagen 
N-terminal peptide (PIIIP) and type IV collagen 7S 
(7s collagen) 
Positive rate* (%) 
Disease n KL-6 PIIIP 7s collagen 
IP 45 80 40 40 
IPF 20 80 25 35 
IP-CVD 10 100 80 60 
Other IP 15 50 33 33 
Alveolar pneumonia 12 0 33 25 
pt <O.OOOl 0.67 0.34 
*Cut-off values of KL-6, PIIIP and 7s collagen 
were determined at 520 U ml - ‘, 0.8 U ml - ’ and 
6 ng ml - ‘, respectively. 
I-Difference of positive and negative numbers between 
interstitial pneumonitis (IP) and alveolar pneumonia. 
IPF, idiopathic pulmonary fibrosis; IP-CVD, IP 
associated with collagen vascular disease. 
While the source of increased KL-6 in sera from 
patients with pneumonitis is limited to type 2 pneu- 
mocytes, type III collagen could be produced by 
type 1 pneumocytes, fibroblasts, myofibroblasts and 
smooth muscle cells, and type IV collagen by type 1 
pneumocytes, capillary endothelial cells and smooth 
muscle cells (16). These observations indicate that the 
histological and physiological significance is different 
among the increases of serum KL-6, PIIIP and 7S 
collagen. This is supported by the present data as 
there were no significant correlations among them. 
Therefore, although the diagnostic value of serum 
KL-6 for IP was clearly superior to that of serum 
PIIIP and 7S collagen, further studies of the clinical 
significance of these markers should be simul- 
taneously examined in the clinical course of large 
numbers of patients with IP. 
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